The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease.
Open accessAbstract
The murine monoclonal antibody mAb-1H11 raised against malondialdehyde (MDA)-modified LDL, was used to detect cross-reacting material in human atheromatous tissue and in plasma. MDA-modified LDL levels in plasma were 0.19 +/- 0.02 mg/dl (mean +/- SEM) in 44 control subjects, 0.24 +/- 0.02 mg/dl in 15 patients with chronic stable angina pectoris (P = NS vs LDL cholesterol matched controls), 1.4 +/- 0.1 mg/dl in 60 patients with acute myocardial infarction (P < 0.001 vs controls), and 0.86 +/- 0.11 mg/dl in 22 patients with carotid atherosclerosis (P < 0.001 vs controls). Modified LDL, isolated from pooled LDL of 10 patients, showed a higher electrophoretic mobility on agarose gels, a higher content of thiobarbituric acid reactive substances, and a higher cholesterol/protein ratio than native LDL and had a similar reactivity (antigen/protein ratio) in the assay as the in vitro MDA-modified LDL used for calibration. Its apo B-100 moiety was not fragmented. Uptake of this modified LDL by macrophages resulted in foam cell generation. In conclusion, elevated plasma levels of atherogenic MDA-modified LDL may be a marker for unstable atherosclerotic cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Havel, R. J., Eder, H. A., & Bragdon, J. H. (1955) · Journal of Clinical Investigation · doi:10.1172/jci103182 · Cited by 8,760
Chemical Coupling of Peptides and Proteins to Polysaccharides by Means of Cyanogen Halides
AXÉN, R., PORATH, J., & ERNBACK, S. (1967) · Nature · doi:10.1038/2141302a0 · Cited by 2,159
The Low-Density Lipoprotein Pathway and its Relation to Atherosclerosis
Goldstein, L. J., & Brown, S. M. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.004341 · Cited by 1,906
Ylä-Herttuala, S., Palinski, W., Rosenfeld, M. E., Parthasarathy, S., Carew, T. E., Butler, S., Witztum, J. L., & Steinberg, D. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114271 · Cited by 1,880
Steinbrecher, U. P., Parthasarathy, S., Leake, D. S., Witztum, J. L., & Steinberg, D. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.12.3883 · Cited by 1,626
Low density lipoprotein undergoes oxidative modification in vivo.
Palinski, W., Rosenfeld, M. E., Ylä-Herttuala, S., Gurtner, G. C., Socher, S. S., Butler, S. W., Parthasarathy, S., Carew, T. E., Steinberg, D., & Witztum, J. L. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.4.1372 · Cited by 1,519
Autoantibody against oxidised LDL and progression of carotid atherosclerosis
Salonen, J. T., Korpela, H., Salonen, R., Nyyssonen, K., Yla-Herttuala, S., Yamamoto, R., Butler, S., Palinski, W., & Witztum, J. L. (1992) · The Lancet · doi:10.1016/0140-6736(92)90926-t · Cited by 1,316
Davies, M. J., Richardson, P. D., Woolf, N., Katz, D. R., & Mann, J. (1993) · Heart · doi:10.1136/hrt.69.5.377 · Cited by 1,127
Fogelman, A. M., Shechter, I., Seager, J., Hokom, M., Child, J. S., & Edwards, P. A. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.4.2214 · Cited by 849
Cited by
Role of Oxidative Modifications in Atherosclerosis
Stocker, R., & Keaney, J. F. (2004) · Physiological Reviews · doi:10.1152/physrev.00047.2003 · Cited by 2,624
Antioxidants and Atherosclerotic Heart Disease
Diaz, M. N., Frei, B., Vita, J. A., & Keaney, J. F. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708073370607 · Cited by 1,353
Antioxidants and Prevention of Chronic Disease
WILLCOX, J. K., ASH, S. L., & CATIGNANI, G. L. (2004) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408690490468489 · Cited by 1,188
Immune Mechanisms in Atherosclerosis
Hansson, G. K. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1201.100220 · Cited by 876
Ehara, S., Ueda, M., Naruko, T., Haze, K., Itoh, A., Otsuka, M., Komatsu, R., Matsuo, T., Itabe, H., Takano, T., et al. (2001) · Circulation · doi:10.1161/01.cir.103.15.1955 · Cited by 781
Plant polyphenols in cancer and heart disease: implications as nutritional antioxidants
Duthie, G. G., Duthie, S. J., & Kyle, J. A. M. (2000) · Nutrition Research Reviews · doi:10.1079/095442200108729016 · Cited by 759
Holvoet, P., Vanhaecke, J., Janssens, S., Van de Werf, F., & Collen, D. (1998) · Circulation · doi:10.1161/01.cir.98.15.1487 · Cited by 673
Self-citationPalinski, W., Hörkkö, S., Miller, E., Steinbrecher, U. P., Powell, H. C., Curtiss, L. K., & Witztum, J. L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118853 · Cited by 559
Immune mechanisms in atherosclerosis.
Hansson, G. K., Jonasson, L., Seifert, P. S., & Stemme, S. (1989) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.9.5.567 · Cited by 515
Oxidized LDL: Diversity, Patterns of Recognition, and Pathophysiology
Levitan, I., Volkov, S., & Subbaiah, P. V. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2733 · Cited by 473
Nagao, T., Komine, Y., Soga, S., Meguro, S., Hase, T., Tanaka, Y., & Tokimitsu, I. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/81.1.122 · Cited by 467
Ballinger, S. W., Patterson, C., Yan, C.-N., Doan, R., Burow, D. L., Young, C. G., Yakes, F. M., Van Houten, B., Ballinger, C. A., Freeman, B. A., et al. (2000) · Circulation Research · doi:10.1161/01.res.86.9.960 · Cited by 442
Toshima, S.-I., Hasegawa, A., Kurabayashi, M., Itabe, H., Takano, T., Sugano, J., Shimamura, K., Kimura, J., Michishita, I., Suzuki, T., et al. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.10.2243 · Cited by 407
JAKUBOWSKI, H. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.15.2277 · Cited by 370
Hörkkö, S., Miller, E., Dudl, E., Reaven, P., Curtiss, L. K., Zvaifler, N. J., Terkeltaub, R., Pierangeli, S. S., Branch, D. W., Palinski, W., et al. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118854 · Cited by 348
Localization of distinct F2-isoprostanes in human atherosclerotic lesions.
Praticò, D., Iuliano, L., Mauriello, A., Spagnoli, L., Lawson, J. A., Rokach, J., Maclouf, J., Violi, F., & FitzGerald, G. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119735 · Cited by 344
Oxidized Low-Density Lipoprotein
Parthasarathy, S., Raghavamenon, A., Garelnabi, M. O., & Santanam, N. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60327-029-8_24 · Cited by 331
Buck, M., & Chojkier, M. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00524.x · Cited by 326
REQUENA, J. R., FU, M. X., AHMED, M. U., JENKINS, A. J., LYONS, T. J., BAYNES, J. W., & THORPE, S. R. (1997) · Biochemical Journal · doi:10.1042/bj3220317 · Cited by 293
Molecular basis of homocysteine toxicity in humans
Jakubowski, H. (2004) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3204-7 · Cited by 255
Shabalala, S. C., Johnson, R., Basson, A. K., Ziqubu, K., Hlengwa, N., Mthembu, S. X. H., Mabhida, S. E., Mazibuko-Mbeje, S. E., Hanser, S., Cirilli, I., et al. (2022) · Antioxidants · doi:10.3390/antiox11102071 · Cited by 102
“However, elevated levels of MDA-mediated adducts have been associated with inflammation and cellular injury, contributing to the development of cardiovascular and chronic liver diseases [44,45].”
Background
Metadata
- Authors
- Holvoet, P., Perez, G., Zhao, Z., Brouwers, E., Bernar, H., & Collen, D.
- Venue
- Journal of Clinical Investigation
- Published
- 1995-06-01
- Volume
- 95
- Issue
- 6
- Pages
- 2611-2619
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2022155347
- Cited by
- 262
- References
- 33
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.